<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479553</url>
  </required_header>
  <id_info>
    <org_study_id>QZTL-V1.0</org_study_id>
    <nct_id>NCT04479553</nct_id>
  </id_info>
  <brief_title>Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.</brief_title>
  <official_title>Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhong Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanxi Zhendong Pharmacy Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry aims to monitor the safety of Qizhi Tongluo Capsules and to identify the
      potential risk factors for its adverse drug reactions.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>The incidence of adverse drug reactions (ADR) to the Qizhi Tongluo Capsules</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse drug event (ADE) to the Qizhi Tongluo Capsules</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of new ADRs to the Qizhi Tongluo Capsules</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of serious adverse drug event (SADE) to the Qizhi Tongluo Capsules</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biological indicators of patients with serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Patients with serious adverse events and suspected unintended serious adverse reactions should be tested for liver function (ALT, AST, ALP, TBIL, DBIL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biological indicators of patients with serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Patients with serious adverse events and suspected unintended serious adverse reactions should be tested for renal function (BUN, SCr, UA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biological indicators of patients with serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Patients with serious adverse events and suspected unintended serious adverse reactions should be tested for immune indicators (IgA, IgE, T-lymphocyte, B lymphocyte, cell surface antigen, serum histamine concentration and complement).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Safety Surveillance</condition>
  <condition>Adverse Drug Events</condition>
  <condition>Adverse Drug Reactions</condition>
  <condition>Severe Adverse Events</condition>
  <condition>Severe Adverse Reactions</condition>
  <arm_group>
    <arm_group_label>Qizhi Tongluo Capsules</arm_group_label>
    <description>Qizhi Tongluo Capsules will be given to the patients, and the investigators will record all the information including ADR, application of Qizhi Tongluo Capsules and the combined medications, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qizhi Tongluo Capsules</intervention_name>
    <description>Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).</description>
    <arm_group_label>Qizhi Tongluo Capsules</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. The blood routine, urine routine, and stool routine before and after medication need to
           be obtained in the patients with adverse events

        2. The level of the liver functional indicators (including ALT,AST,ALP,TBIL,DBIL) the renal
           functional indicators (including BUN,SCr,UA) and the immune indicators (including
           IgA，IgE,the counts of T lymphocyte and B lymphocyte,CD3，CD4，CD8，CD20,serum histamine
           concentration,C3,C4) should be obtained in patients with serious adverse events and
           suspicious unexpected serious adverse reactions.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who use Qizhi Tongluo Capsules in the monitoring hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who use Qizhi Tongluo Capsules in the monitoring hospitals.

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhong wang</last_name>
    <phone>86-10-64093305</phone>
    <email>zhonw@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Luohe Hospital of traditional Chinese Medicine</name>
      <address>
        <city>Luohe</city>
        <state>Henan</state>
        <zip>462000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yingmin Song</last_name>
      <phone>13623957063</phone>
      <email>sym26567@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanyang Medical College</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lijun Lu</last_name>
      <phone>13782162323</phone>
      <email>13782162323@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of traditional Chinese Medicine</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinzhi Wang</last_name>
      <phone>18638189355</phone>
      <email>znqznq@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Henan University of traditional Chinese Medicine</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinsheng Zhang</last_name>
      <phone>18003820038</phone>
      <email>zjssir2OO4@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Yanbian University</name>
      <address>
        <city>Yanbian</city>
        <state>Jilin</state>
        <zip>133000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shengzhe Zheng</last_name>
      <phone>15526770326</phone>
      <email>mikezheng23@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Changzhi Institute of traditional Chinese Medicine</name>
      <address>
        <city>Changzhi</city>
        <state>Shanxi</state>
        <zip>046000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinbin Guo</last_name>
      <phone>13111251707</phone>
      <email>changzhizynb@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zhong Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

